

Y-Trap | Private Company Profile

Highlights




PitchBook Analyst Coverage

Biopharma Mature Modalities

Fundraising

From Series B

40 Months Since Last Deal



Post Valuation

\$52.13M

As of 09-Dec-2022

Valuation Step-up

2.25x

Early Stage VC (Series A) - Early Stage VC (Series B)



VC Exit Predictor: Exit Type

No Exit - 82% Probability

Out of 66,630 companies with Opportunity Score



Employees

10

As of 20-Feb-2026



Last Deal Details

\$25.13M [£]

Early Stage VC (Series B) 09-Dec-2022

Total Raised to Date

\$27.13M

As of 09-Dec-2022

VC Exit Predictor: Opportunity Score

14



Out of 66,630 companies with Opportunity Score

General Information

Description

Developer of immuno-oncology technologies designed for cancer immunotherapy. The company's patented technology is a novel platform of targeted multi-functional immunomodulatory antibody-ligand traps for cancer immunotherapy, enabling physicians to avail targeted immunotherapeutic strategies for many types of advanced and treatment-refractory cancers.

Most Recent Financing Status (as of 08-Mar-2023)

The company raised an estimated \$25.14 million through a combination of Series B-1 and Series B-2 venture funding from undisclosed investors on December 9, 2022, putting the company's pre-money valuation at \$27 million.

Website	www.y-trap.com	Year Founded	2018
Entity Type	Private Company	Universe	Venture Capital
Legal Name	Y-Trap, Inc.	Employees	10
Business Status	Startup		
Ownership Status	Privately Held (backing)		
Financing Status	Venture Capital-Backed		
LinkedIn URL	Y-Trap		

Industries, Verticals & Keywords

Primary PitchBook Industry	Verticals	Keywords	GECS Sector
Biotechnology	Life Sciences Oncology	cancer biology cancer immunotherapy cancer therapy immune care immune checkpoint inhibitors monoclonal antibody	Healthcare
			GECS Industry Group
			Biotechnology
			GECS Industry
			Biotechnology

Appears in PitchBook Analyst Market Map

Q4 2025 Biopharma (VC Ecosystem) 3,027 Companies	Q3 2025 Biopharma (VC Ecosystem) 4,176 Companies Ben Riccio	Q2 2025 Biopharma (VC Ecosystem) 4,009 Companies Ben Riccio
2025 Biopharma Modalities Overview (2025 Q1) 3,829 Companies		

Contact Information

Primary Contact

[Atul Bedi MD](#)
Co-Founder & Chief Scientist
atul@y-trap.com

Primary Office

1 Tower Place
Suite 800
San Francisco, CA 94080
United States
info@y-trap.com

Alternate Offices

Baltimore
1812 Ashland Avenue
Suite 110
Baltimore, MD 21205
United States
info@y-trap.com

Top 5 Similar Companies

#	Name	Competitor	Financing Status	HQ Location	Primary Industry	Year Founded	Last Financing Date/Type	Last Financing Amount
1	Bristol-Myers Squibb		Corporation	Princeton, NJ	Drug Discovery	1887	2024/Debt - Acquisition	\$13.00B
2	Merck & Co.		Corporation	Rahway, NJ	Pharmaceuticals	1891	2025/PIPE	\$1.64M
3	Genentech		Formerly VC-backed	South San Francisco, CA	Pharmaceuticals	1976	2009/2ndary - Open	\$46.80B
4	Amgen		Formerly PE-Backed	Thousand Oaks, CA	Drug Discovery	1980	2026/Debt Refin.	\$4.00B
5	Regeneron Pharmaceuticals		Formerly VC-backed	Tarrytown, NY	Pharmaceuticals	1988	2020/Repurchase	\$2.00B

Comparisons

	 Y-Trap	 Volastra	 Aro Biotherapeutics	 Vita Therapeutics
Description	Developer of immuno-oncology technologies designed for cancer immunotherapy.	Operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease.	Developer of a protein drug platform designed to unlock the potential of genetic medicines.	Operator of a cellular therapeutics and cell engineering company intended for the treatment of debilitating neuromuscular diseases and cancers.
Primary Industry	Biotechnology	Drug Discovery	Drug Discovery	Drug Discovery
HQ Location	San Francisco, CA	New York, NY	Philadelphia, PA	Baltimore, MD
Employees	10 2026	41 2025	49 2024	9 2026
Total Raised	\$27.13M	\$149.10M	\$131.84M	\$65.70M
Post Valuation	\$52.13M 09-Dec-2022	\$150.60M 23-Sep-2025	\$181.50M 28-Nov-2023	\$87.00M 23-Jun-2021